IBDEI0VH ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14750,1,4,0)
 ;;=4^G91.2
 ;;^UTILITY(U,$J,358.3,14750,2)
 ;;=^5004174^F02.81
 ;;^UTILITY(U,$J,358.3,14751,0)
 ;;=G91.2^^53^613^23
 ;;^UTILITY(U,$J,358.3,14751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14751,1,3,0)
 ;;=3^NPH w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,14751,1,4,0)
 ;;=4^G91.2
 ;;^UTILITY(U,$J,358.3,14751,2)
 ;;=^5004174^F02.80
 ;;^UTILITY(U,$J,358.3,14752,0)
 ;;=G30.8^^53^613^5
 ;;^UTILITY(U,$J,358.3,14752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14752,1,3,0)
 ;;=3^Alzheimer's Diseases NEC
 ;;^UTILITY(U,$J,358.3,14752,1,4,0)
 ;;=4^G30.8
 ;;^UTILITY(U,$J,358.3,14752,2)
 ;;=^5003807
 ;;^UTILITY(U,$J,358.3,14753,0)
 ;;=G31.09^^53^613^16
 ;;^UTILITY(U,$J,358.3,14753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14753,1,3,0)
 ;;=3^Frontotemporal Dementia NEC
 ;;^UTILITY(U,$J,358.3,14753,1,4,0)
 ;;=4^G31.09
 ;;^UTILITY(U,$J,358.3,14753,2)
 ;;=^329916
 ;;^UTILITY(U,$J,358.3,14754,0)
 ;;=G20.^^53^613^24
 ;;^UTILITY(U,$J,358.3,14754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14754,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,14754,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,14754,2)
 ;;=^5003770^F02.81
 ;;^UTILITY(U,$J,358.3,14755,0)
 ;;=G20.^^53^613^25
 ;;^UTILITY(U,$J,358.3,14755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14755,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,14755,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,14755,2)
 ;;=^5003770^F02.80
 ;;^UTILITY(U,$J,358.3,14756,0)
 ;;=G31.01^^53^613^26
 ;;^UTILITY(U,$J,358.3,14756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14756,1,3,0)
 ;;=3^Pick's Disease
 ;;^UTILITY(U,$J,358.3,14756,1,4,0)
 ;;=4^G31.01
 ;;^UTILITY(U,$J,358.3,14756,2)
 ;;=^329915
 ;;^UTILITY(U,$J,358.3,14757,0)
 ;;=G23.1^^53^613^28
 ;;^UTILITY(U,$J,358.3,14757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14757,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia
 ;;^UTILITY(U,$J,358.3,14757,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,14757,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,14758,0)
 ;;=Z79.2^^53^614^1
 ;;^UTILITY(U,$J,358.3,14758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14758,1,3,0)
 ;;=3^Antibiotics
 ;;^UTILITY(U,$J,358.3,14758,1,4,0)
 ;;=4^Z79.2
 ;;^UTILITY(U,$J,358.3,14758,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,14759,0)
 ;;=Z79.01^^53^614^2
 ;;^UTILITY(U,$J,358.3,14759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14759,1,3,0)
 ;;=3^Anticoagulants
 ;;^UTILITY(U,$J,358.3,14759,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,14759,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,14760,0)
 ;;=Z79.02^^53^614^3
 ;;^UTILITY(U,$J,358.3,14760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14760,1,3,0)
 ;;=3^Antiplatelets/Antithrombotics
 ;;^UTILITY(U,$J,358.3,14760,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,14760,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,14761,0)
 ;;=Z79.82^^53^614^4
 ;;^UTILITY(U,$J,358.3,14761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14761,1,3,0)
 ;;=3^Aspirin
 ;;^UTILITY(U,$J,358.3,14761,1,4,0)
 ;;=4^Z79.82
 ;;^UTILITY(U,$J,358.3,14761,2)
 ;;=^5063340
 ;;^UTILITY(U,$J,358.3,14762,0)
 ;;=Z79.4^^53^614^5
 ;;^UTILITY(U,$J,358.3,14762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14762,1,3,0)
 ;;=3^Insulin
 ;;^UTILITY(U,$J,358.3,14762,1,4,0)
 ;;=4^Z79.4
 ;;^UTILITY(U,$J,358.3,14762,2)
 ;;=^5063334
 ;;^UTILITY(U,$J,358.3,14763,0)
 ;;=Z79.1^^53^614^7
 ;;^UTILITY(U,$J,358.3,14763,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14763,1,3,0)
 ;;=3^NSAID
 ;;^UTILITY(U,$J,358.3,14763,1,4,0)
 ;;=4^Z79.1
 ;;^UTILITY(U,$J,358.3,14763,2)
 ;;=^5063332
